methyl 3-oxo-3,4-dihydro-2H-1,5-benzodioxepin-2-carboxylate | 27648-88-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 3-oxo-3,4-dihydro-2H-1,5-benzodioxepin-2-carboxylate
• 英文别名: methyl 3,4-dihydro-3-oxo-2H-1,5-benzodioxepine-2-carboxylate；4-Carbomethoxy-3,4-dihydro-2H-1,5-benzodioxepin-3-on；3-oxo-4-carbomethoxy-3,4-dihydro-2H-1,5-benzodioxepin；3-oxo-3,4-dihydro-2H-benzo[b][1,4]dioxepine-2-carboxylic acid methyl ester；methyl 3-oxo-1,5-benzodioxepine-4-carboxylate
• CAS: 27648-88-0
• 化学式: C₁₁H₁₀O₅
• 分子量: 222.197
• InChiKey: QWITYISTGJEZKV-UHFFFAOYSA-N

物化性质

• 沸点：
  343.9±42.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 3-oxo-3,4-dihydro-2H-1,5-benzodioxepin-2-carboxylate 在 盐酸 作用下， 以 异丙醇 为溶剂， 生成 2H-1,5-苯并二氧-3(4h)-酮
  参考文献：
  名称：

  1,5-Benzodioxepin衍生物是新型的毒蕈碱M3受体拮抗剂。

  摘要：

  报告了新型毒蕈碱M（1）-M（3）受体拮抗剂的新型1,5-苯并二恶英衍生物的结构活性关系。发现其中一些化合物对毒蕈碱M（3）受体具有高结合亲和力，并且对口服后未麻醉的大鼠膀胱压力节律性增加有有效作用。这些化合物对唾液腺显示出对膀胱的选择性。

  DOI：

  10.1016/j.bmcl.2006.11.058
• 作为产物：
  描述：

  2,2'-[(1,2-phenylene)bis(oxy)]bis[acetic acid] dimethyl ester 在 sodium hydride 作用下， 以 二甲基亚砜 、 甲苯 为溶剂， 生成 methyl 3-oxo-3,4-dihydro-2H-1,5-benzodioxepin-2-carboxylate
  参考文献：
  名称：

  1,5-Benzodioxepin衍生物是新型的毒蕈碱M3受体拮抗剂。

  摘要：

  报告了新型毒蕈碱M（1）-M（3）受体拮抗剂的新型1,5-苯并二恶英衍生物的结构活性关系。发现其中一些化合物对毒蕈碱M（3）受体具有高结合亲和力，并且对口服后未麻醉的大鼠膀胱压力节律性增加有有效作用。这些化合物对唾液腺显示出对膀胱的选择性。

  DOI：

  10.1016/j.bmcl.2006.11.058

文献信息

• 3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-ben
  申请人：Merck & Co., Inc.

  公开号：US03944560A1

  公开（公告）日：1976-03-16

  3-Hydroxy-3-(substituted-aminoalkyl-3,4-dihydro-2H-1,5-benzodioxepin products are described that exhibit .sym.-advenergic stimulating properties and are therefore suitable for use as bronchodilating agents. The products are prepared essentially by four principal routes from 3-oxo-3,4-dihydro-2H-1,5-benzodioxepins. By one route the 3-oxobenzodioxepin is treated with a nitroalkane to give a 3-hydroxy-3-nitroalkyl-benzodioxepin the nitro group of which is reduced to an amine and the resulting compound reacted with an aldehyde or ketone under hydrogenating conditions to introduce the desired substituent into the amino function. By a second route the 3-oxobenzodioxepin is reacted with an alkali metal nitrile to form the cyanhydrin which upon reduction forms the 3-hydroxy-3-aminoalkyl-benzodioxepin that can be treated with a ketone or aldehyde to give the desired products or can be reacted with sodium nitrite or other agent to form a 3-spiro-benzodioxepin-2-oxirane which upon reaction with an amine provides the desired product. The 3-spiro-benzodioxepin-2'-oxirane also can be obtained by treatment of the 3-oxo-benzodioxepin with a sulfurylide, A fourth method involves forming a benzodioxepin-3-spiro-5'-oxazolidin-2'-one which upon treatment with dilute alkali gives the desired 3-hydroxy-3-(substituted aminoalkyl)-3,4-dihydro-2H-1,5-benzodioxepin The intermediate oxazolidinone compounds can be treated if desired with various agents to attach substituents on the benzenoid moiety of the starting substance. These oxazolidinones exhibit .beta. -stimulating and skeletal muscle relaxant properties.

  描述了具有β-肾上腺素激动性能的3-羟基-3-(取代氨基烷基-3,4-二氢-2H-1,5-苯并二氧杂环己啶产品，因此适用于用作支气管扩张剂。这些产品基本上是通过从3-氧代-3,4-二氢-2H-1,5-苯并二氧杂环己啶制备的四种主要途径而制备的。通过一种途径，3-氧代苯并二氧杂环己啶与硝基烷烃反应，得到一种3-羟基-3-硝基烷基苯并二氧杂环己啶，其硝基被还原为胺，然后将所得化合物在加氢条件下与醛或酮反应，将期望的取代基引入氨基功能中。通过第二种途径，3-氧代苯并二氧杂环己啶与碱金属腈反应形成氰水合物，还原后形成3-羟基-3-氨基烷基苯并二氧杂环己啶，可以用酮或醛处理以得到期望的产物，也可以与亚硝酸钠或其他试剂反应形成3-螺苯并二氧杂环己啶-2-环氧烷，后者与胺反应提供所需的产物。3-螺苯并二氧杂环己啶-2'-环氧烷也可以通过将3-氧代苯并二氧杂环己啶与磺酰亚砜处理而获得，第四种方法涉及形成苯并二氧杂环己啶-3-螺-5'-噁唑烷-2'-酮，后者在稀碱处理后给出所需的3-羟基-3-(取代氨基烷基)-3,4-二氢-2H-1,5-苯并二氧杂环己啶。如果需要，可以用各种试剂处理这些中间噁唑烷酮化合物，以在起始物质的苯环部分上连接取代基。这些噁唑烷酮表现出β-激动和骨骼肌松弛性能。
• 1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonists
  作者：Shuji Sonda、Kenichi Katayama、Masakazu Fujio、Hiroshi Sakashita、Kenichi Inaba、Kiyoshi Asano、Toshiaki Akira

  DOI：10.1016/j.bmcl.2006.11.058

  日期：2007.2

  The structure-activity relationships of novel 1,5-benzodioxepin derivatives as muscarinic M(1)-M(3) receptor antagonists are reported. Some of these compounds were found to possess high binding affinity for the muscarinic M(3) receptor and potent effect on rhythmic increase in bladder pressure in unanesthetized rats following oral administration. These compounds displayed selectivity for the bladder

  报告了新型毒蕈碱M（1）-M（3）受体拮抗剂的新型1,5-苯并二恶英衍生物的结构活性关系。发现其中一些化合物对毒蕈碱M（3）受体具有高结合亲和力，并且对口服后未麻醉的大鼠膀胱压力节律性增加有有效作用。这些化合物对唾液腺显示出对膀胱的选择性。
• 2-(piperazinylalkyl)-1-benzothiepin, 1-benzoxepin, and 1,5-benzodioxepin
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04736031A1

  公开（公告）日：1988-04-05

  Novel condensed seven-membered heterocyclic compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy, R.sub.3 and R.sub.4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom, X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated, Y is >C.dbd.O or >CH--OR.sub.5 in which R.sub.5 is hydrogen, acyl or optionally substituted carbamoyl, A is oxygen atom or sulfur atom, E is oxygen atom or methylene, and G is lower alkylene, provided that when A is sulfur atom, E is methylene, and salts thereof exhibit serotonin S.sub.2 receptor blocking activity, actions to relieve cerebral vasospasm and antithrombotic activity, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.

  本发明涉及一种化合物，其为七元杂环化合物，化学式为：##STR1## 其中R.sub.1和R.sub.2分别为氢、卤素、羟基、低碳基或低烷氧基；R.sub.3和R.sub.4分别为氢、可选取代的低碳基、可选取代的环烷基或可选取代的芳基烷基；或者两者共同形成一个可选取代的环，与相邻的氮原子一起；X为氢、可选取代的低碳基、可选取代的芳基或可酯化或酰胺化的羧基；Y为>C.dbd.O或>CH--OR.sub.5，其中R.sub.5为氢、酰基或可选取代的氨基甲酰基；A为氧原子或硫原子；E为氧原子或亚甲基；G为低碳基亚烷基。当A为硫原子时，E为亚甲基。该化合物的盐表现出5-羟色胺S.sub.2受体阻断活性，缓解脑血管痉挛和抗血栓活性，可作为缺血性心脏病、血栓形成、高血压和脑循环障碍的预防和治疗剂。
• Condensed seven-membered heterocyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0205264A1

  公开（公告）日：1986-12-17

  Novel condensed seven-membered heterocyclic compounds of the formula: wherein R, and R2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy, R3 and R4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom, X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated, Y is C=O or CH-OR5 in which Rs is hydrogen, acyl or optioinally substituted carbamoyl, A is an oxygen atom or sulfur atome, E is an oxygen atom or methylene, and G is lower alkylene, provided that when A is a sulfur atom, E is methylene, and salts thereof exhibit serotonin S2 receptor blocking activity, actions to relieve cerebral vasospasm and antithrombotic activity, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.

  式中的新型缩合七元杂环化合物： 其中 R 和 R2 独立地为氢、卤素、羟基、低级烷基或低级烷氧基、 R3和R4独立地为氢、任选取代的低级烷基、任选取代的环烷基或任选取代的芳烷基，或两者与相邻的氮原子共同形成任选取代的环、 X 是氢、任选取代的低级烷基、任选取代的芳基或可酯化或酰胺化的羧基、 Y 是 C=O 或 CH-OR5，其中 Rs 是氢、酰基或被选择取代的氨基甲酰基、 A 是氧原子或硫原子，E 是氧原子或亚甲基，以及 G 是低级亚烷基，条件是当 A 是硫原子时，E 是亚甲基、 及其盐类具有 5-羟色胺 S2 受体阻断活性、缓解脑血管痉挛的作用和抗血栓活性，具有作为 具有预防和治疗缺血性心脏病、血栓形成、高血压和脑循环障碍的价值。
• Schroth,W.; Werner,B., Zeitschrift fur Chemie, 1970, vol. 10, # 10, p. 382 - 383
  作者：Schroth,W.、Werner,B.

  DOI：——

  日期：——